Effects of efpeglenatide on weight, BMI, and waist circumference in those with obesity without diabetes stratified by baseline characteristics: subanalysis of BALANCE 205
Sorli C, Pratley R, Jacob S, Kang J, Trautmann M, Hompesch M, Han O, Stewart J, Ogbaa I, Yoon K Poster presented at 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain. 2019 Sept.Relationship between glycaemic control and weight loss with once-weekly efpeglenatide in uncontrolled type 2 diabetes: a subanalysis of EXCEED 203
Michael Trautmann, Rosenstock J, Morales C, Wendisch U, Dailey G, Hompesch M, Choi IY, Kang J, Stewart J, Ogbaa I, Sorli C, Yoon K Poster presented at 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain. 2019 Sept.Efficacy of efpeglenatide in patients with obesity and prediabetes: a subanalysis of the BALANCE 205 study
Ogbaa I, Pratley R, Jacob S, Kang J, Trautmann M, Hompesch M, Han O, Stewart J, Sorli C, Yoon K Poster presented at 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain. 2019 Sept.Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study
Pratley, R.E.; Jacob, S; Kang, J; Trautmann, M.E.; Hompesch, M; Han, O; Stewart, J.A.; Ogbaa, I; Sorli, C.H.; Yoon, K. Presentation at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.NGM313, a Novel Activator of β-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects
Depaoli, A; Phung, V; Bashir, M.R.; Morrow, L; Beysen, C; Yan, A; Ling, L; Baxter, B; Luskey, K.L.; Olefsky, J.M. Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese
Choi, J.D.; Baek, S; Kim, Y; Eun, K; Kwon, S.C.; Morrow, L; Hompesch, M; Kang, J Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205
Pratley, R.E.; Jacob, S; Kang, J; Trautmann, M.E.; Hompesch, M; Han, O; Stewart, J.A.; Ogbaa, I; Sorli, C.H.; Yoon, K Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203
Rosenstock, J; Morales Sr., C; Wendisch, U; Dailey III, G.E.; Trautmann, M.E.; Hompesch, M; Choi, I.Y.; Kang, J; Stewart, J.A.; Ogbaa, I; Sorli, C.H.; Yoon, K Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?
Dailey III, G.E.; Rosenstock, J; Morales Sr., C; Wendisch, U; Trautmann, M.E.; Hompesch, M; Choi, I.Y.; Kang, J; Sorli, C.H.; Ogbaa, I; Stewart, J.A.; Yoon, K Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.Relationship Between Controlled Attenuation Parameter (CAP) and Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) in Subjects at High Risk for Nonalcoholic Fatty Liver Disease (NAFLD)
Heidi Guthrie, Natalia Castro, Carine Beysen, Linda Morrow and Marcus Hompesch
Poster presented at the NASH-TAG Conference, Park City, UT. 2019 Jan 3-5.
MEDI4166, a novel antibody-peptide fusion molecule: multiple-ascending-dose study in patients with type 2 diabetes
Carlson, G; Cook, W; Morrow, L; Petrone, M; White, N; Wang, T; Ambery, P; Hirshberg, B; Jain, M Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany. 2018 Oct.Impact of praliciguat, a soluble guanylate cyclase stimulator, on blood pressure and metabolic parameters in patients with diabetes and hypertension
Seferovic, J.P.; Wilson, P; Carlson, K.E.; Jung, J; Wakefield, J.D.; Miller, P; Chickering, J.G.; Morrow, L; Currie, M.G.; Milne, G.T.; Profy, A.T.; Hanrahan, J.P. Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany. 2018 Oct.The effect of efpeglenatide on lipid profiles and overall metabolism in patients with type 2 diabetes and obese patients without diabetes
Yoon, K; Kang, J; Choi, I; Trautmann, M; Hompesch, M; Sorli, C; Pratley, R Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany. 2018 Oct.Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements
Xiaosu, M.A.; Prescilla, R.P.; Zhang, S; Linnebjerg, H; Morrow, L; Jackson, J.A.; Johnson, J; Leishman, D Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist—Immunogenicity Profile Based on Preclinical and Clinical Studies
Del Prato, S; Choi, I.Y.; Kang, J; Trautmann, M.E.; Yoon, K; Sorli, C.H. Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)—Evidence from Preclinical, Modeling, and Clinical Studies
Rosenstock, J; Trautmann, M.E.; Hompesch, M; Choi, I.Y.; Kang, J; Yoon, K; Sorli, C.H. Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.Fourteen-Day Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension
Hanrahan, J.P.; Wakefield, J.D.; Wilson, P.J.; Miller, P; Chickering, J; Morrow, L; Hall, M.L.; Currie, M; Milne, G.T.; Profy, A.T. Presentation at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.The novel glucagon receptor agonist SAR438544, first in human safety, pharmacokinetic and pharmacodynamic data from a study in healthy volunteers
Hompesch, M; Grosjean, P; Morrow, L; Hijazi, Y; Ishibai, M; Teichert, L; Bergmann, K Poster presented at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal. 2017 Sept.Weight loss unrelated to decrease in calorie intake after a single dose of a bispecific antibody to FGFR1/Klothoβ in obese subjects
Arora, P.S.; Wong, C; Baruch, A; Chinn, L; Vaze, A; Sonoda, J; Gelzleichter, T; Chen, S; Lewin-Koh, N; Morrow, L; Boismenu, R Presentation at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal. 2017 Sept.MEDI4166, a novel antibody (PCSK9)-peptide (GLP-1) fusion molecule: single-ascending-dose study in patients with type 2 diabetes
Jain, M; Cook, W; Morrow, L; Petrone, M; Pu, W; Ambery, P; Hirshberg, B; Carlson, G Poster presented at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal. 2017 Sept.To inquire about additional poster presentations, please contact abby.devine@prosciento.com. To receive updates about new publications and poster presentations, please click here.